|
In vitro studies
|
| Colon carcinoma |
SW480 |
169.24 μM |
70.53% |
NA |
5
|
| Non-small cell lung carcinoma, breast carcinoma |
A549, BT20 |
100 μM |
99.1%, 99.7% |
26.3 μM, 11.8 μM (IC50) |
6
|
| Non-small cell lung carcinoma, ovarian carcinoma, skin malignant melanoma, central nervous system tumor, adenocarcinomas of the colon and rectum |
A549, SK-OV-3, SK-MEL-2, XF498, HCT15 |
NA |
NA |
31.73 μM, 35.96 μM, 46.54 μM, 48.66 μM, 38.08 μM (IC50) |
2
|
| Hepatocarcinoma, ovarian carcinoma, prostatic carcinoma, non-small cell lung carcinoma, endometrial carcinoma, esophageal carcinoma, glioma, gastric carcinoma, gastric adenocarcinoma |
SMM-7721,Bel-7402, H08910, PC-3M,A549, HCT-8,CaEs-17,U251, BGC-823,SGC-7901 |
42.31 μM |
91.9%, 86.8%,82.1%, 86.6%, 91.4%, 77.8%,88.9%, 83.3%, 81.6%, 83.6% |
8.08 μM,13.71 μM,12.63 μM,13.18 μM,11.11 μM,13.31 μM,12.10 μM,15.76 μM,15.46 μM,13.58 μM (IC50) |
7
|
| Promyelocytic leukemia, leukemia, lymphoma, lymphomatic leukemia, hepatocarcinoma, gastric carcinoma |
HL-60,U-937, P-388, L-1210, HepG-2, SNU-C5 |
NA |
NA |
42.6 μM, 19.3 μM, 61.0 μM, 49.4 μM, 8.9 μM, 42.8 μM (IC50) |
8
|
| Prostatic carcinoma |
DU145 |
211.55 μM |
74% |
NA |
12
|
| Promyelocytic leukemia |
HL-60 |
10–40 μM, 40–50 μM |
Inhibited, cell lethal |
NA |
13
|
| Colon carcinoma |
LoVo |
4.0 μM |
91.35% |
17 μM (IC50) |
15
|
| Melanoma, ovarian carcinoma, colon adenocarcinoma, breast adenocarcinoma, non-small cell lung carcinoma, thyroid carcinoma |
518A2, A2780, HT29, MCF7, A549, 8505C |
NA |
NA |
34.9 μM, 19.9 μM, 50.0 μM, 25.7 μM, 29.0 μM, 38.0 μM (EC50) |
17
|
| Hepatocarcinoma |
HePG2 |
NA |
NA |
16.04 μM (IC50) |
21
|
| Colon carcinoma |
LoVo |
105.78 μM |
86% |
NA |
22
|
| Gastric carcinoma |
MGC-803 |
105.78 μM |
86.89% |
NA |
23
|
| |
|
In vivo studies
|
|
|
|
|
|
| Breast carcinoma, non-small cell lung carcinoma, hepatocarcinoma, gastric carcinoma, colon carcinoma, ovarian carcinoma, endometrial carcinoma, myeloid leukemia, esophageal squamous carcinoma |
MCF-7, A549, Hep3B, MGC-803, LoVo, HO-8910PM, HEC-1, K562, Eca-109 bearing BALB/c nude mice |
405 mg kg−1
|
65%, 69.56%, 65.57%, 70.69%, 69.49%, 68.85%, 70.97%, 71.88%, 69.84% |
NA |
9
|
| Hepatocarcinoma |
H22 bearing mice |
200 mg kg−1
|
42.75% |
NA |
11
|
| Head and neck cancer |
HN9-cisR bearing nude mice |
200 mg kg−1
|
Suppressed |
NA |
14
|
